Tumor markers for bladder cancer: outlook for routine use

被引:0
|
作者
Ecke, Thorsten H. [1 ]
机构
[1] HELIOS Klinikum Bad Saarow, Urol Klin, D-15526 Bad Saarow Pieskow, Germany
来源
LABORATORIUMSMEDIZIN-JOURNAL OF LABORATORY MEDICINE | 2010年 / 34卷 / 02期
关键词
bladder cancer; tumor marker; urothelial cell carcinoma; TRANSITIONAL-CELL CARCINOMA; TISSUE POLYPEPTIDE ANTIGEN; IN-SITU HYBRIDIZATION; GROWTH-FACTOR RECEPTOR-3; CARE PROTEOMIC ASSAY; TP53; GENE-MUTATIONS; URINARY-BLADDER; FOLLOW-UP; CLINICAL-IMPLICATIONS; UROTHELIAL CARCINOMA;
D O I
10.1515/JLM.2010.021
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
This article outlines the role of bladder cancer tumor markers in diagnosis and therapy with a particular focus on the most important biomarkers. A MEDLINE based literature search was performed to examine the field of bladder cancer markers. Further determination of recurrence and progression markers will contribute to establish better treatments for the individual patient. Molecular staging of urological tumors will allow selecting cases that will require systemic treatment. Therapeutically, knowledge of cancer progression pathways allows for drug therapies against specific tumor targets. It is necessary and important to integrate under the same objectives basic translational and clinical research.
引用
收藏
页码:77 / 86
页数:10
相关论文
共 50 条
  • [21] Tumor markers of bladder cancer: the schistosomal bladder tumors versus non-schistosomal bladder tumors
    Ahmed S Abdulamir
    Rand R Hafidh
    Haider S Kadhim
    Fatimah Abubakar
    Journal of Experimental & Clinical Cancer Research, 28
  • [22] Evaluation of two new urinary tumor markers:: Bladder tumor fibronectin and cytokeratin 18 for the diagnosis of bladder cancer
    Sánchez-Carbayo, M
    Urrutia, M
    de Buitrago, JMG
    Navajo, JA
    CLINICAL CANCER RESEARCH, 2000, 6 (09) : 3585 - 3594
  • [23] Bladder cancer - Outlook for advanced forms
    Bertetto, O
    Mistrangelo, M
    TUMORI, 2003, : S114 - S117
  • [24] (Invasive) Bladder Cancer - an interdisciplinary Outlook
    Gschwend, J. E.
    Lorch, A.
    Roedel, C.
    Schmidberger, H.
    ONKOLOGE, 2018, 24 (01): : 2 - 4
  • [25] Routine Use of Photodynamic Diagnosis of Bladder Cancer: Practical and Economic Issues
    Zaak, Dirk
    Wieland, Wolf F.
    Stief, Christian G.
    Burger, Maximilian
    EUROPEAN UROLOGY SUPPLEMENTS, 2008, 7 (07) : 536 - 541
  • [26] Markers for bladder cancer
    Grossman, HB
    JOURNAL OF CLINICAL LIGAND ASSAY, 2002, 25 (01): : 80 - 82
  • [27] Considerations on the use of diagnostic markers in management of patients with bladder cancer
    Piyush K. Agarwal
    Peter C. Black
    Ashish M. Kamat
    World Journal of Urology, 2008, 26 : 39 - 44
  • [28] Considerations on the use of diagnostic markers in management of patients with bladder cancer
    Agarwal, Piyush K.
    Black, Peter C.
    Kamat, Ashish M.
    WORLD JOURNAL OF UROLOGY, 2008, 26 (01) : 39 - 44
  • [29] Clinical Utility of Tumor Markers and Cytokines Assessment in Patients with Bladder Cancer
    Fuksiewicz, M.
    Kotowicz, B.
    Kaminska, J.
    Kowalska, M.
    Wisniewski, T.
    Rogowski, W.
    Demkow, T.
    TUMOR BIOLOGY, 2008, 29 : 53 - 53
  • [30] BIOCHEMICALLY DETECTABLE TUMOR MARKERS IN URINE OF BLADDER CANCER-PATIENTS
    IRVING, CC
    CANCER RESEARCH, 1977, 37 (08) : 2872 - 2874